Trial Profile

Pharmacokinetics of Single and Multiple Doses of HA121-28 Tablets and Exploration of Maximum Tolerated Dose in Patients With Advanced Solid Tumor in Phase I Clinical Trial

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 07 Feb 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs HA121 28 (Primary)
Indications Advanced breast cancer; Cholangiocarcinoma; Colon cancer; Liver cancer; Lung cancer; Nasopharyngeal cancer; Non-small cell lung cancer; Solid tumours; Thyroid cancer
Focus Adverse reactions
Sponsors CSPC ZhongQi Pharmaceutical Technology

Most Recent Events

07 Feb 2024 According to ClinicalTrials.gov, the recruitment status of this study is unknown because the information has not been verified recently (last verified Feb 2022 )
08 Feb 2022 Planned End Date changed from 30 Dec 2020 to 30 Dec 2022.
08 Feb 2022 Planned primary completion date changed from 30 Aug 2020 to 30 Dec 2022.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com